Introduction
============

Although the value of postoperative radiotherapy (PORT) in completely resected Stage IIIA-pN2 non-small-cell lung cancer (NSCLC) is still controversial, there has been interest in the use of PORT to improve the outcomes for the Stage IIIA-pN2 NSCLC patients because they have different levels of risk of local relapse and metastasis.[@b1-ott-9-6161],[@b2-ott-9-6161] Large clinical trials have confirmed the efficacy of point of care testing (POCT) in completely resected Stages II and III NSCLC patients.[@b3-ott-9-6161]--[@b5-ott-9-6161] Multidisciplinary treatment modalities can be conducted to enhance the local control and to increase the overall survival (OS) rate by introducing PORT. A meta-analysis in 1998 showed that PORT was detrimental to patients with completely resected NSCLC, especially for those with Stage I/II, N0--N1 disease.[@b6-ott-9-6161] Lally et al[@b7-ott-9-6161] found that PORT was only beneficial to the patients in the postoperative pN2 category. An analysis of the Surveillance, Epidemiology, and End Results database showed that although PORT had a detrimental effect on survival for patients with pN0 or pN1 disease, it was associated with longer survival for patients with pN2 disease.[@b7-ott-9-6161] In addition, a subgroup analysis of the Adjuvant Navelbine International Trialist Association (ANITA) trial showed that PORT led to longer OS in patients with resected pN2 NSCLC, both in the chemotherapy arm and in the observation arm.[@b8-ott-9-6161] Patients with Stage IIIA-pN2 NSCLC have a poor long-term OS rate, which was estimated at 24% in the analysis of the Surveillance, Epidemiology, and End Results database.[@b9-ott-9-6161] However, patients with Stage IIIA-pN2 NSCLC are a heterogeneous group with different clinicopathologic features. Thus, there may be significant variability in survival among this heterogeneous group. The mediastinal lymph node (LN) metastasis should be taken into consideration. We aimed to find out whether the style of the LN metastasis is predictive for the prognosis of the Stage IIIA-N2 disease and the necessity for the PORT.

Methods
=======

We retrospectively analyzed 220 cases of Stage IIIA-N2 NSCLC patients who underwent resection at Tianjin Medical Collage Cancer Hospital from January 1, 2008 to December 30, 2010. Patients who received induction therapy (radiotherapy or chemotherapy) were not included in this study. There were 32 cases of pneumonectomy, and 188 cases of lobectomy or tumor excision. All the patients were proven to have N2 disease according to the postoperative pathology. All the patients received postoperative chemotherapy, therefore 43 received postoperative chemoradiotherapy (POCRT) (including eleven cases of concurrent and 32 cases of sequential disease). The patients who did not receive PORT were grouped as POCT group, and the 43 patients who received PORT were defined as POCRT group. The follow-up information was obtained by outpatient care and through telephone follow-up. The prognosis (local relapse or distant metastasis) was confirmed by pathology and imaging (computed tomography scan, magnetic resonance imaging, or positron emission tomography). The cases with follow-up time \<3 months were excluded. The chemotherapy regimens were four cycles of intravenously administered docetaxel (75 mg/m^2^)/paclitaxel (175 mg/m^2^) and cisplatin (75 mg/m^2^) for nonadenocarcinoma and docetaxel (75 mg/m^2^)/paclitaxel (175 mg/m^2^)/pemetrexed (500 mg/m^2^) and cisplatin (75 mg/m^2^) for adenocarcinoma, with an interval of 3 weeks. Patients received a total radiotherapy dose of 50.4 Gy (in 28 fractions; 1.8 Gy per fraction) using a linear accelerator, 6 MV X-rays. This study was approved by the Regional Ethics Committee of Tianjin Medical University Cancer Institute and Hospital and all patients signed informed consents. The clinical trial number is LUC201103.

Statistical analysis
--------------------

The progression-free survival (PFS) survival was defined as the time period from the date of the surgery to progression or the date of last visit. The OS was defined as the time period from the date of the surgery to death or the date of last visit. The local recurrence-free survival (LRFS) was defined as the time period from the date of the surgery to the date of local recurrence, and the distant metastasis-free survival (DMFS) was defined as the time period from the date of the surgery to the date of distant metastasis, or the date of last visit. The skip metastasis was defined as pN0N2 (no N1 LN involved) and nonskip metastasis was pN1N2 (one or more N1 LNs involved). Survival was analyzed using the Kaplan--Meier method, and differences in survival were determined by the log-rank test. *P*\<0.05 was considered statistically significant. Statistical calculations were conducted with SPSS17.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

All the 220 cases were included in the survival analysis, the clinicopathological characteristics of all the patients are listed in [Table 1](#t1-ott-9-6161){ref-type="table"}. The average resected N1 LNs, N2 LNs, and N1 + N2 LNs were 6.96±5.51 (2--32), 15.25±0.65 (3--58), and 22.33±0.82 (5--67), respectively; the average number of LN stations for N1, N2, and N1 + N2 were 1.59±0.85 (1--3), 4.25±1.75 (1--9), and 5.85±2.14 (3--11), respectively ([Table 2](#t2-ott-9-6161){ref-type="table"}). There were 83 cases in the LN skip group, 137 cases in the LN nonskip group. Forty-three cases received POCRT, whereas 177 cases received POCT. The median PFS, OS, LRFS, and DMFS of the total 220 patients were 13.0, 31.0, 22.0, and 18 months, respectively, and the 3-year PFS, OS, LRFS, and DMFS were 20.0%, 41.8%, 34.1%, and 25%, respectively.

Survival analysis based on LN skip status
-----------------------------------------

The median 3-year PFS was, respectively, 16 months (27.7%) for the LN skip group and 11 months (15.3%) for the LN nonskip group (*P*=0.001). The median 3-year OS was, respectively, 35 months (47.0%) for the LN skip group and 27 months (38.7%) for the LN nonskip group (*P*=0.025). The median 3-year LRFS was, respectively, 25 months (41.0%) for the LN skip group and 19 months (29.9%) for the LN nonskip group (*P*=0.014). The median 3-year DMFS was, respectively, 22 months (32.5%) for the LN skip group and 15 months (20.4%) for the LN nonskip group (*P*=0.013) ([Table 3](#t3-ott-9-6161){ref-type="table"}; [Figure 1](#f1-ott-9-6161){ref-type="fig"}).

Survival based on PORT
----------------------

The median 3-year PFS was, respectively, 17 months (25.6%) for the POCRT group and 12 months (18.6%) for the POCT group (*P*=0.037). The median 3-year OS was, respectively, 37 months (51.2%) for the POCRT group and 30 months (39.5%) for the POCT group (*P*=0.295). The median 3-year LRFS was, respectively, 24 months (39.5%) for the POCRT group and 22 months (32.8%) for the POCT group (*P*=0.282). The median 3-year DMFS was, respectively, 20 months (32.6%) for the POCRT group and 15 months (23.2%) for the POCT group (*P*=0.136) ([Table 4](#t4-ott-9-6161){ref-type="table"}; [Figure 2](#f2-ott-9-6161){ref-type="fig"}).

Subgroup analysis by LN skip status for PORT
--------------------------------------------

In the LN skip group, the median 3-year PFS was, respectively, 23 months (36.8%) for the POCRT subgroup and 13.0 months (25%) for the POCT subgroup (*P*=0.098). The median 3-year OS was, respectively, 37 months (52.6%) for the POCRT subgroup and 34 months, 45.3% for the POCT subgroup (*P*=0.536). The median 3-year LRFS was, respectively, 37 months (52.6%) for the POCRT subgroup and 23 months (37.5%) for the POCT subgroup (*P*=0.111). The median 3-year DMFS was, respectively, 23 months (36.8%) for the POCRT subgroup and 20 months (31.3%) for the POCT subgroup (*P*=0.501). In the nonskip group, the median 3-year PFS was, respectively, 14 months (36.8%) for the POCRT subgroup and 9 months (25%) for the POCT subgroup (*P*=0.301). The median 3-year OS was, respectively, 31 months (50%) for the POCRT subgroup and 26 months (36.3%) for the POCT subgroup (*P*=0.429). The median 3-year LRFS was, respectively, 18 months (29.2%) for the POCRT subgroup and 19 months (30.1%) for the POCT subgroup (*P*=0.843). The median 3-year DMFS was, respectively, 18 months (29.2%) for the POCRT subgroup and 15 months (18.6%) for the POCT subgroup (*P*=0.843) ([Table 5](#t5-ott-9-6161){ref-type="table"}; [Figures 3](#f3-ott-9-6161){ref-type="fig"}[](#f4-ott-9-6161){ref-type="fig"}[](#f5-ott-9-6161){ref-type="fig"}--[6](#f6-ott-9-6161){ref-type="fig"}).

Discussion
==========

The rationale for PORT as an adjuvant treatment is that it is most likely to be effective against microscopic tumor cells, which, without intervention, will progress to macroscopically detectable dimensions. According to this rationale, patients with advanced T stage and mediastinal LN involvement might benefit from PORT and may have a better locoregional control and OS after surgery.[@b10-ott-9-6161]--[@b16-ott-9-6161] However, the value of PORT in completely resected Stage IIIA-pN2 NSCLC is still controversial. In 2010, a retrospective analysis[@b17-ott-9-6161] showed that PORT significantly reduced local recurrence, but had no impact on OS. In 2011, another retrospective study[@b18-ott-9-6161] reported that a significantly lower rate of distant metastasis with PORT was observed. Feng et al,[@b13-ott-9-6161] in a randomized study enrolling 366 patients, showed that PORT prevents locoregional recurrence without a statistically significant impact on survival. In 2013, a meta-analysis[@b19-ott-9-6161] showed that in Stage IIIA-N2 NSCLC patients, linear accelerator-based PORT could increase the absolute OS by 13%. In the ANITA trial, the addition of PORT to resection and adjuvant chemotherapy increased the 5-year survival from 34% to 47% in pN2 disease.

Actually, patients with Stage IIIA-pN2 NSCLC are a heterogeneous group with different clinicopathological features. This reminds us that treatments for the Stage IIIA-N2 NSCLC should be individualized. Several clinical and pathological factors have been taken into consideration to evaluate the progress of Stage IIIA NSCLC disease and the effect of PORT, while avoiding unnecessary damage associated with PORT. Mantovani et al[@b20-ott-9-6161] reported that patients with multiple pathologically involved nodal stations should be treated more aggressively with systemic agents because of the higher risk of systemic failure, which is significantly higher than the risk of local failure. Matsuguma et al[@b21-ott-9-6161] reported that the number of mediastinal LN stations was predictive for the PORT treatment. Urban et al[@b22-ott-9-6161] reported that the LN ratio has been proposed as a useful prognostic metric in NSCLC,[@b23-ott-9-6161]--[@b26-ott-9-6161] a high LN ratio was predictive of the benefit of PORT. Moretti et al[@b27-ott-9-6161] speculated that a positive extracapsular extension status may be an indicator of the risk of distant metastatic disease in NSCLC -- the extracapsular extension might be a predictive factor for the use of PORT.

The LN skip status has been proven to be predictive for the prognosis of the NSCLC patients.[@b28-ott-9-6161] The so-called "skip phenomenon" has been described in the clinical setting[@b29-ott-9-6161]--[@b31-ott-9-6161] and has objectively been documented by anatomic study[@b32-ott-9-6161] \>20 years ago. In Legras et al's[@b28-ott-9-6161] opinion, the "skip phenomenon" corresponds to this direct lymph drainage from the tumor to the mediastinum by vessels derived from intrapulmonary LN and does not correspond to intrapulmonary LN not having intercepted tumor cells drained by their lymphatic vessels. The skip N2 cases show the involvement of one channel directly connected to the mediastinal LNs, whereas nonskip N2 showed involvement of two channels, the former channel connected to the mediastinal LN directly and the other channel that went through the N1 LNs to the mediastinal LNs. More channels resulted in higher risk of recurrence and metastasis.[@b33-ott-9-6161] In the current study, as the results showed, the POCRT resulted in better PFS, with statistically significant difference, though the POCRT group showed better OS than the POCT group, but there was no statistical difference. The LN skip group showed better PFS and OS than the LN nonskip group; the result was consistent with Antoine's result, and we also found that the LRFS and DMFS of the LN skip group were better than that of the LN nonskip group. In subgroup analysis, the results showed that there was no statistical significance in the Kaplan--Meier analysis between subgroups, but the subgroup analysis also showed that POCRT resulted in better PFS, OS, and DMFS in both LN skip and LN nonskip subgroups, and this advantage was more obvious in the LN skip subgroup. All the above showed a trend that PORT has more obvious advantage in the LN skip group in improving survival.

The limitation of our study includes the retrospective nature of the study and the different sample sizes between different comparison arms, which may influence our results seriously. Moreover, in clinical treatment, the number of N2 stations or the number of positive LNs could influence the selection for POCT and POCRT, and this selection bias might influence our results too. Therefore, randomized prospective studies with large sample size are indispensable for the individualized PORT treatment.

Conclusion
==========

The LN skip status is closely related to the survival of the Stage IIIA-N2 NSCLC disease. The LN skip (pN0N2) patients may get more benefit in PFS and LRFS from PORT than the LN nonskip (pN1N2) patients, but randomized prospective studies with large sample sizes are needed to prove it.
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![Survival curves of the LN skip group and LN nonskip group.\
**Notes:** The median 3-year PFS was, respectively, 16 months (27.7%) for the LN skip group and 11 months (15.3%) for the LN nonskip group, *P*=0.001; the median 3-year OS was, respectively, 35 months (47.0%) for the LN skip group and 27 months (38.7%) for the LN nonskip group, *P*=0.025. The median 3-year LRFS was, respectively, 25 months (41%) for the LN skip group and 19 months (29.9%) for the LN nonskip group, *P*=0.014. The median 3-year DMFS was, respectively, 22 months (32.5%) for the LN skip group and 15 months (20.4%) for the LN nonskip group, *P*=0.013.\
**Abbreviations:** LN, lymph node; PFS, progression-free survival; OS, overall survival; LRFS, local recurrence-free survival; DMFS, distant metastasis-free survival.](ott-9-6161Fig1){#f1-ott-9-6161}

![Survival curves of the POCRT group and POCT group.\
**Notes:** The median 3-year PFS was, respectively, 17 months (25.6%) for the POCRT group and 12 months (18.6%) for the POCT group, *P*=0.037. The median 3-year OS was, respectively, 37 months (51.2%) for the POCRT group and 30 months (39.5%) for the POCT group, *P*=0.295. The median 3-year LRFS was, respectively, 24 months (39.5%) for the POCRT group and 22 months (32.8%) for the POCT group, *P*=0.282. The median 3-year DMFS was, respectively, 20 months (32.6%) for the POCRT group and 15 months (23.2%) for the POCT group, *P*=0.136.\
**Abbreviations:** POCRT, postoperative chemoradiotherapy; POCT, point of care testing; PFS, progression-free survival; OS, overall survival; LRFS, local recurrence-free survival; DMFS, distant metastasis-free survival.](ott-9-6161Fig2){#f2-ott-9-6161}

![PFS curves of subgroup analysis.\
**Notes:** In the LN skip group, median 3-year PFS was, respectively, 23 months (36.8%) for the POCRT subgroup and 13.0 months (25%) for the POCT subgroup (*P*=0.098). In the nonskip group, median 3-year PFS was, respectively, 14 months (36.8%) for the POCRT subgroup and 9 months (25%) for the POCT subgroup (*P*=0.301).\
**Abbreviations:** PFS, progression-free survival; LN, lymph node; POCRT, postoperative chemoradiotherapy; POCT, point of care testing.](ott-9-6161Fig3){#f3-ott-9-6161}

![OS curves of subgroup analysis.\
**Notes:** In the LN skip group, the median 3-year OS was, respectively, 37 months (52.6%) for the POCRT subgroup and 34 months (45.3%) for the POCT subgroup, *P*=0.536. In the nonskip group, the median 3-year OS was, respectively, 31 months (50%) for the POCRT subgroup and 26 months (36.3%) for the POCT subgroup, *P*=0.429.\
**Abbreviations:** OS, overall survival; LN, lymph node; POCRT, postoperative chemoradiotherapy; POCT, point of care testing.](ott-9-6161Fig4){#f4-ott-9-6161}

![LRFS curves of subgroup analysis.\
**Notes:** In the LN skip group, the median 3-year LRFS was, respectively, 37 months (52.6%) for the POCRT subgroup and 23 months (37.5%) for the POCT subgroup, *P*=0.111. In the nonskip group, the median 3-year LRFS was 18 months, 29.2% for the POCRT subgroup and 19 months, 30.1% for the POCT subgroup, *P*=0.843.\
**Abbreviations:** LRFS, local recurrence-free survival; LN, lymph node; POCRT, postoperative chemoradiotherapy; POCT, point of care testing.](ott-9-6161Fig5){#f5-ott-9-6161}

![DMFS curves of subgroup analysis.\
**Notes:** In the LN skip group, the median 3-year DMFS was, respectively, 23 months (36.8%) for the POCRT subgroup and 20 months (31.3%) for the POCT subgroup, *P*=0.501. In the nonskip group, the median 3-year DMFS was, respectively, 18 months (29.2%) for the POCRT subgroup and 15 months (18.6%) for the POCT subgroup, *P*=0.843.\
**Abbreviations:** DMFS, distant metastasis-free survival; LN, lymph node; POCRT, postoperative chemoradiotherapy; POCT, point of care testing.](ott-9-6161Fig6){#f6-ott-9-6161}

###### 

Patient characteristics

  Variable                    PORT, n   Non-PORT, n
  --------------------------- --------- -------------
  Sex                                   
   Male                       30        107
   Female                     13        70
  Age (years)                           
   \<60                       27        93
   ≥60                        16        84
  Histology                             
   Adenocarcinoma             12        102
   Nonadenocarcinoma          31        75
  Surgical procedure                    
   Pneumonectomy              10        22
   Lobectomy/tumor excision   33        155
  T stage                               
   T1                         15        60
   T2--3                      28        117
  Positive N2 stations                  
   Single                     18        95
   Multiple                   25        82
  Positive LN ratio                     
   ≤25%                       23        100
   \>25%                      20        77
  LN skip                               
   Skip                       19        64
   Nonskip                    24        113
  Total                       43        177

**Abbreviations:** PORT, postoperative radiotherapy; LN, lymph node.

###### 

Resected lymph nodes and lymph node stations

  Lymph nodes condition         Mean ± SD    Minimum to maximum, n
  ----------------------------- ------------ -----------------------
  N1 lymph nodes                6.96±5.51    (2--32)
  N2 lymph nodes                15.25±0.65   (3--58)
  N1 + N2 lymph nodes           22.33±0.82   (5--67)
  N1 lymph node stations        1.59±0.85    (1--3)
  N2 lymph node stations        4.25±1.75    (1--9)
  N1 + N2 lymph node stations   5.85±2.14    (3--11)

**Abbreviation:** SD, standard deviation.

###### 

Survival analysis based on LN skip status

  Survival           LN skip   LN nonskip   *P*-value
  ------------------ --------- ------------ -----------
  PFS                                       
   Median (months)   16        11           0.001
   3-year PFS        27.7%     15.3%        
  OS                                        
   Median (months)   35        27           0.025
   3-year OS         47%       38.7%        
  LRFS                                      
   Median (months)   25        19           0.014
   3-year LRFS       41%       29.9%        
  DMFS                                      
   Median (months)   22        15           0.013
   3-year DMFS       32.5%     20.4%        

**Abbreviations:** LN, lymph node; OS, overall survival; PFS, progression-free survival; LRFS, local recurrence-free survival; DMFS, distant metastasis-free survival.

###### 

Survival based on POCRT and POCT

  Survival           POCRT   POCT    *P*-value
  ------------------ ------- ------- -----------
  PFS                                
   Median (months)   17      12      0.037
   3-year PFS        25.6%   18.6%   
  OS                                 
   Median (months)   37      30      0.295
   3-year OS         51.2%   39.5%   
  LRFS                               
   Median (months)   24      22      0.282
   3-year LRFS       39.5%   32.8%   
  DMFS                               
   Median (months)   20      15      0.136
   3-year DMFS       32.6%   23.2%   

**Abbreviations:** PORT, postoperative radiotherapy; POCRT, postoperative chemoradiotherapy; POCT, point of care testing; OS, overall survival; PFS, progression-free survival; LRFS, local recurrence-free survival; DMFS, distant metastasis-free survival.

###### 

Survival of subgroups

  Subgroup      POCRT   POCT   *P*-value          
  ------------- ------- ------ ----------- ------ -------
  PFS                                             
   LN skip      23      36.8   13          25     0.098
   LN nonskip   14      16.7   9           15.0   0.301
  OS                                              
   LN skip      37      52.6   34          45.3   0.536
   LN nonskip   31      50     26          36.3   0.429
  LRFS                                            
   LN skip      37      52.6   23          37.5   0.111
   LN nonskip   18      29.2   19          30.1   0.843
  DMFS                                            
   LN skip      23      36.8   20          31.3   0.501
   LN nonskip   18      29.2   15          18.6   0.224

**Abbreviations:** POCRT, postoperative chemoradiotherapy; POCT, point of care testing; PFS, progression-free survival; LN, lymph node; OS, overall survival; LRFS, local recurrence-free survival; DMFS, distant metastasis-free survival.
